Introduction
An estimated 2.6 million children live with HIV, and antiretroviral therapy (ART) has led to increasing numbers surviving into adolescence, a proportion of whom are heavily ART-experienced [1, 2] . Maraviroc (MVC) is licensed in treatment-experienced adults and when given with a boosted protease inhibitor (bPI) offers convenient once-daily dosing [3] . While phase 2 safety and efficacy studies of twice-daily MVC in treatment-experienced children aged 2-17 years are ongoing (A4001031), prior offlicence paediatric use has occurred as a consequence of HIV-1-associated resistance mutations limiting ART options, ART toxicity, and for simplification to once-daily regimens in adolescents struggling with adherence [4, 5] . In the single previous reported study of the paediatric use of MVC in salvage therapy (n = 20), all patients received MVC twice daily [6] . In the vast majority of perinatally infected infants, the transmitted strain utilizes the C-C chemokine receptor type 5 (CCR5) coreceptor with the subsequent emergence of X4 virus [7] . In a retrospective analysis of a UK perinatal cohort, 80% of children aged 12 years had R5-using virus, falling to 50% at entry to adult care, for whom MVC remained a treatment option [8] .
This analysis describes the clinical experience of the offlicence use of once-daily MVC prescribed on the recommendation of a regional paediatric virtual clinic (PVC) in a cohort of perinatally infected children and adolescents.
Methods
We carried out a retrospective case note analysis of children with perinatally acquired HIV infection (PaHIV) who received MVC as part of their ART between September 2010 and June 2015 on the recommendation of the PVC previously described [9] . Baseline data collection included gender, ethnicity, age, weight, previous ART exposure/toxicity, viral clade, HIV-1-associated resistance mutations, viral tropism, reason for referral to the PVC, CD4 count and viral load (VL) at initiation of MVC ART, dose of MVC and ART regimen. Follow-up data included CD4 and VL response, side effects attributed to MVC, current weight and dose of MVC. Viral suppression was defined as a plasma HIV polymerase chain reaction (PCR) measurement of < 50 HIV-1 RNA copies/mL. Where available, plasma MVC therapeutic drug monitoring (TDM) was performed by an approved partner laboratory with a minimum concentration (C min ) of 50 ng/mL as the cut-off for virological efficacy. Data were anonymized and entered into an Excel spreadsheet recording absolute numbers, percentages, medians and interquartile ranges (IQRs).
Results

Demographics
Twenty-two children received once-daily MVC ART. Their median age at initiation was 14 years (IQR: 12-15 years; range 8-17 years) with seven aged < 13 years. Ten (45%) were female, 13 (59%) black African, five (23%) Caucasian, two (9%) Asian, one (4%) black American and one of unknown ethnicity. Reasons for referral to the PVC included: virological failure (VF) in 13 patients (59%); ART toxicity on suppressive therapy in five patients (23%), which was attributable to tenofovir (TDF)-associated nephrotoxicity in four patients; requests for simplification to once-daily regimens in four patients (18%) who were adolescents struggling with adherence to twice-daily regimens. The patients had received a median of 3 previous ART regimens (range 2-5), with cumulative HIV-1-associated resistance mutations as follows: dual class, 86% (19 of 22); triple class, 14% (three of 22). Seventy-seven per cent of patients had a non-B clade virus.
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We report the first paediatric experience of the off-licence use of oncedaily maraviroc with a boosted protease inhibitor and optimized backbone in 22 treatment-experienced adolescents with R5 HIV. Seventy-one per cent maintained a suppressed viral load for a median of 139 weeks with safety and tolerability comparable to those found in adult studies.
Tropism and ART regimens
All patients had a documented CCR5 tropic virus on RNA (HIV plasma VL > 500 copies/mL) or DNA V3 loop sequencing (HIV plasma VL < 500 copies/mL) within 3 months prior to switching to MVC ART. Twenty-one of the 22 children (95%) received MVC with a bPI, either darunavir/ritonavir (DRV/r) (19 patients; 90%) or atazanavir/ritonavir (two patients; 10%), and an optimized backbone. Five children also received an integrase inhibitor [raltegravir (RAL), three patients; dolutegravir (DTG), two patients] and two received etravirine. One adolescent, with previous severe allergies to multiple bPIs, received a unique regimen of MVC, DTG, abacavir, lamivudine and TDF.
MVC dosing and TDM
MVC ART was initiated at a median weight of 45.5 kg (IQR: 36-58 kg; range 23-72 kg), with seven patients (32%) weighing < 40 kg, the weight cut-off most frequently used for adult ART dosing. All received 300 mg once daily with a bPI with the exception of one child, age 8 years, weight 23 kg, who received 150 mg once daily. None of the patients with TDF-associated nephrotoxicity had significant renal impairment requiring a dosage adjustment for MVC. TDM was available for eight patients, with a weight range of 23-65 kg, a median time post MVC dose of 13 h 45 min (range 5 h 0 min to 16 h 50 min), and a median concentration of 126 ng/mL (range: undetectable to 483 ng/mL). Two patients had a C min of < 50 ng/mL, both with known adherence issues and detectable viraemia.
Outcomes
Follow-up data were available for 21 of the 22 patients. At the start of MVC ART, the median CD4 count was 577 cells/lL (IQR: 275-910 cells/lL) and the median VL was 157 copies/mL (IQR < 50-10 600 copies/mL), with two patients having VL > 100 000 copies/mL and seven patients (32%) having viral suppresson, switching for ART toxicity (four patients) and simplification (three patients). At the latest follow-up, the median duration of MVC exposure was 139 weeks (IQR: 96-187 weeks; range 10-256 weeks), the median CD4 count was 775 cells/lL (IQR: 581-956 cells/lL), and 15 of 21 patients (71%) had a VL < 50 copies/mL. Four patients had low-level viraemia of 50-600 copies/mL and two patients had discontinued MVC ART because of gastrointestinal toxicity (one patient) or virological failure (one patient) after 
Toxicity
Three patients reported nausea after commencing MVC ART, which resolved in two of them within 4 weeks without antiemetics; however, one adolescent on MVC, DRV/r and TDF/emtricitabine (Truvada Gilead Sciences Intl Ltd, Cambridge UK) stopped MVC at 8 weeks and briefly achieved suppression on DRV/r and Truvada, before VF with self-reported poor adherence. One adolescent developed a transient rash (grade 1) within 2 weeks of starting MVC, DRV/r and Truvada that resolved without a change in ART. No symptoms consistent with postural hypotension were reported. One adolescent with known excessive alcohol intake developed a grade 4 rise in alanine aminotransferase (ALT) > 8 times the upper limit of normal but continued on suppressive MVC, DRV/r, TDF and raltegravir.
Discussion
MVC is currently unlicensed for use in children despite its approval for treatment-experienced adults in 2007, almost a decade ago. Off-licence use of MVC has occurred in a small number of children and adolescents but to date only twice-daily use has been described [6] .
On the recommendation of the PVC, 22 children and adolescents received ART regimens that included offlicence use of once-daily MVC that was generally well tolerated, with only one adolescent stopping MVC because of gastrointestinal toxicity, and no additional side effects to those previously reported in the adult MOTIVATE and MERIT trials were observed [3] . In the interim analysis of the ongoing paediatric trial A4001031 of twice-daily MVC, 18% of patients experienced treatment-related side effects, all mild to moderate, most frequently gastrointestinal [10] .
Regarding efficacy, of the 14 children who were viraemic at the start of MVC ART, 86% ever achieved virological suppression, with two-thirds remaining suppressed at a median of 104 weeks, comparable to response rates seen in treatment-experienced adults, in the single reported study of the off-label use of twice-daily MVC in adolescents and within the interim analysis of the ongoing paediatric study MVC A4001031 [3, 5, 6, 10] . Of those who switched to MVC ART while on suppressive ART, all remained suppressed after a median of 156 weeks.
TDM was available for eight patients; six achieved plasma MVC levels greater than a predicted C min of 50 ng/ mL, the predicted level for virological success. The remaining two patients have known adherence issues. Interim analysis of twice-daily MVC pharmacokinetic data in A4001031 using body surface area (BSA) dosing suggests that, while scaled down adult BSA dosing is effective for regimens with potent cytochrome 3A4 inhibitors, doses are likely to be higher than adult BSA scaled doses in paediatric regimens that do not contain a protease inhibitor [12] .
The use of MVC once daily with a bPI and optimized backbone, while outside the current adult licence, is widely used in clinical practice [11] . While there are concerns regarding the efficacy of nucleoside-sparing regimens that include a bPI and MVC in both treatment-na€ ıve and suppressed adults, in this cohort of treatmentexperienced children, once-daily MVC with a bPI and optimized nucleoside backbone appeared well tolerated, convenient and efficacious. The small numbers and retrospective nature of this cohort limit interpretation but highlight the need for randomized controlled trials of once-daily versus twice-daily MVC with a bPI and more broadly the development of paediatric pipelines that reflect equity of access to antiretroviral agents available to their parents.
